why choose us

First received: August 18, 2023

Clinical Trial: Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Metastatic Triple-Negative Breast Carcinoma

Study Type: INTERVENTIONAL


Official Title: Pilot Clinical Trial Examining the Safety and Efficacy of Neratinib in Combination With Ruxolitinib in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer With Chest Wall Re

Brief Summary: The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer.This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.

Read more